Novel role of IL-6/SIL-6R signaling in the expression of inducible nitric oxide synthase (iNOS) in murine B16, metastatic melanoma clone F10.9, cells

Free Radical Biology and Medicine

Volumn 42, Issue 2, 2007, Pages 215-227

  Kang, Keon Wook ^a   Wagley, Yadav ^a   Kim, Hyun Woo ^a   Pokharel, Yuba Raj ^a   Chung, Yoon Young ^a   Chang, In Youb ^a   Kim, Jong Joong ^a   Moon, Jeong Seok ^a   Kim, Youn Kyu ^b   Nah, Seung Yeol ^c   Kang, Hyung Sik ^d   Oh, Jae Wook ^a  

^a Chosun University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c Konkuk University   (South Korea)

^d Chonnam National University   (South Korea)

Author keywords

Cell Activation; Cytokines; Nitric Oxide; Transcription Factors

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CHIMERIC PROTEIN; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 6 RECEPTOR INTERLEUKIN 6 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; MELANOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; INTERLEUKIN-6; MAP KINASE KINASE 4; MELANOMA; MICE; NITRIC OXIDE SYNTHASE TYPE II; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTORS, INTERLEUKIN-6; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1;

MURINAE;

EID: 33845638280     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2006.10.034     Document Type: Article

References (72)

1. Taga T., and Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol. 15 (1997) 797-819
2. Kamimura D., Ishihara K., and Hirano T. IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev. Physiol. Biochem. Pharmacol. 149 (2003) 1-38
3. Aderka D., Le J.M., and Vilcek J. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J. Immunol. 143 (1989) 3517-3523
4. Mullberg J., Schooltink H., Stoyan T., Gunther M., Graeve L., Buse G., Mackiewicz A., Heinrich P.C., and Rose-John S. The soluble interleukin-6 receptor is generated by shedding. Eur. J. Immunol. 23 (1993) 473-480
5. Oh J.W., Revel M., and Chebath J. A soluble interleukin 6 receptor isolated from conditioned medium of human breast cancer cells is encoded by a differentially spliced mRNA. Cytokine 8 (1996) 401-409
6. Novick D., Engelmann H., Wallach D., and Rubinstein M. Soluble cytokine receptors are present in normal human urine. J. Exp. Med. 170 (1989) 1409-1414
7. Frieling J.T., Sauerwein R.W., Wijdenes J., Hendriks T., and van der Linden C.J. Soluble interleukin 6 receptor in biological fluids from human origin. Cytokin 6 (1994) 376-381
8. Honda M., Yamamoto S., Cheng M., Yasukawa K., Suzuki H., Saito T., Osugi Y., Tokunaga T., and Kishimoto T. Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. J. Immunol. 148 (1992) 2175-2180
9. Kyrtsonis M.C., Dedoussis G., Zervas C., Perifanis V., Baxevanis C., Stamatelou M., and Maniatis A. Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma. Br. J. Haematol. 93 (1996) 398-400
10. Kotake S., Sato K., Kim K.J., Takahashi N., Udagawa N., Nakamura I., Yamaguchi A., Kishimoto T., Suda T., and Kashiwazaki S. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J. Bone Miner. Res. 11 (1996) 88-95
11. Lu C., and Kerbel R.S. Cytokines, growth factors and the loss of negative growth controls in the progression of human cutaneous malignant melanoma. Curr. Opin. Oncol. 6 (1994) 212-220
12. Oh J.W., Katz A., Harroch S., Eisenbach L., Revel M., and Chebath J. Unmasking by soluble IL-6 receptor of IL-6 effect on metastatic melanoma: growth inhibition and differentiation of B16-F10.9 tumor cells. Oncogene 15 (1997) 569-577
13. Chebath J., Fischer D., Kumar A., Oh J.W., Kolett O., Lapidot T., Fischer M., Rose-John S., Nagler A., Slavin S., and Revel M. Interleukin-6 receptor- interleukin-6 fusion proteins with enhanced interleukin-6 type pleiotropic activities. Eur. Cytokine Netw. 8 (1997) 359-365
14. Kollet O., Aviram R., Chebath J., ben-Hur H., Nagler A., Shultz L., Revel M., and Lapidot T. The soluble interleukin-6 (IL-6) receptor/IL-6 fusion protein enhances in vitro maintenance and proliferation of human CD34(+)CD38(-/low) cells capable of repopulating severe combined immunodeficiency mice. Blood 94 (1999) 923-931
15. Kamaraju A.K., Bertolotto C., Chebath J., and Revel M. Pax3 down-regulation and shut-off of melanogenesis in melanoma B16/F10.9 by interleukin-6 receptor signaling. J. Biol. Chem. 277 (2002) 15132-15141
16. Geller D.A., and Billiar T.R. Molecular biology of nitric oxide synthases. Cancer Metastasis Rev. 17 (1998) 7-23
17. Massi D., Franchi A., Sardi I., Magnelli L., Paglierani M., Borgognoni L., Maria Reali U., and Santucci M. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions. J. Pathol. 194 (2001) 194-200
18. Xie K., Huang S., Dong Z., Juang S.H., Gutman M., Xie Q.W., Nathan C., and Fidler I.J. Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J. Exp. Med. 181 (1995) 1333-1343
19. Oh J.W., Drabik K., Kutsch O., Choi C., Tousson A., and Benveniste E.N. CXC chemokine receptor 4 expression and function in human astroglioma cells. J. Immunol. 166 (2001) 2695-2704
20. Kang K.W., Choi S.Y., Cho M.K., Lee C.H., and Kim S.G. Thrombin induces nitric-oxide synthase via Galpha12/13-coupled protein kinase C-dependent I- kappaBalpha phosphorylation and JNK-mediated I-kappaBalpha degradation. J. Biol. Chem. 278 (2003) 17368-17378
21. Cho M.K., Suh S.H., and Kim S.G. JunB/AP-1 and NF-kappa B-mediated induction of nitric oxide synthase by bovine type I collagen in serum-stimulated murine macrophages. Nitric Oxide 6 (2002) 319-332
22. Lazar-Molnar E., Hegyesi H., Toth S., and Falus A. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 12 (2000) 547-554
23. Geller D.A., Nussler A.K., Di Silvio M., Lowenstein C.J., Shapiro R.A., Wang S.C., Simmons R.L., and Billiar T.R. Cytokines, endotoxin, and glucocorticoids regulate the expression of inducible nitric oxide synthase in hepatocytes. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 522-526
24. Merial-Kieny C., Lonchampt M., Coge F., Verwaerde P., Galizzi J.P., Boutin J.A., Lafontan M., Levens N., Galitzky J., and Feletou M. Endothelin-1 inhibits TNF alpha-induced iNOS expression in 3T3-F442A adipocytes. Br. J. Pharmacol. 139 (2003) 935-944
25. Katsuyama K., Shichiri M., Marumo F., and Hirata Y. Role of nuclear factor-kappaB activation in cytokine- and sphingomyelinase-stimulated inducible nitric oxide synthase gene expression in vascular smooth muscle cells. Endocrinology 139 (1998) 4506-4512
26. Salvucci O., Kolb J.P., Dugas B., Dugas N., and Chouaib S. The induction of nitric oxide by interleukin-12 and tumor necrosis factor-alpha in human natural killer cells: relationship with the regulation of lytic activity. Blood 92 (1998) 2093-2102
27. Woo E.R., Lee J.Y., Cho I.J., Kim S.G., and Kang K.W. Amentoflavone inhibits the induction of nitric oxide synthase by inhibiting NF-kappaB activation in macrophages. Pharmacol. Res. 51 (2005) 539-546
28. Xie Q.W., Kashiwabara Y., and Nathan C. Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J. Biol. Chem. 269 (1994) 4705-4708
29. Chen C.W., Chao Y., Chang Y.H., Hsu M.J., and Lin W.W. Inhibition of cytokine-induced JAK-STAT signalling pathways by an endonuclease inhibitor aurintricarboxylic acid. Br. J. Pharmacol. 137 (2002) 1011-1020
30. Lee B.S., Kang H.S., Pyun K.H., and Choi I. Roles of tyrosine kinases in the regulation of nitric oxide synthesis in murine liver cells: modulation of NF- kappa B activity by tyrosine kinases. Hepatology 25 (1997) 913-919
31. Eferl R., and Wagner E.F. AP-1: a double-edged sword in tumorigenesis. Nat. Rev. Cancer 3 (2003) 859-868
32. Nielsen M., Kaltoft K., Nordahl M., Ropke C., Geisler C., Mustelin T., Dobson P., Svejgaard A., and Odum N. Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 6764-6769
33. Singh R.P., Dhawan P., Golden C., Kapoor G.S., and Mehta K.D. One-way cross-talk between p38(MAPK) and p42/44(MAPK). Inhibition of p38(MAPK) induces low density lipoprotein receptor expression through activation of the p42/44(MAPK) cascade. J. Biol. Chem. 274 (1999) 19593-19600
34. Bennett B.L., Sasaki D.T., Murray B.W., O'Leary E.C., Sakata S.T., Xu W., Leisten J.C., Motiwala A., Pierce S., Satoh Y., Bhagwat S.S., Manning A.M., and Anderson D.W. SP600125, an anthrapyrazolone inhibitor of Jun N- terminal kinase. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 13681-13686
35. Means T.K., Pavlovich R.P., Roca D., Vermeulen M.W., and Fenton M.J. Activation of TNF-alpha transcription utilizes distinct MAP kinase pathways in different macrophage populations. J. Leukoc. Biol. 67 (2000) 885-893
36. Jones S.A., Horiuchi S., Topley N., Yamamoto N., and Fuller G.M. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. Faseb J. 15 (2001) 43-58
37. Tilg H., Dinarello C.A., and Mier J.W. IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol. Today 18 (1997) 428-432
38. Fattori E., Cappelletti M., Costa P., Sellitto C., Cantoni L., Carelli M., Faggioni R., Fantuzzi G., Ghezzi P., and Poli V. Defective inflammatory response in interleukin 6-deficient mice. J. Exp. Med. 180 (1994) 1243-1250
39. Kleinert H., Wallerath T., Fritz G., Ihrig-Biedert I., Rodriguez-Pascual F., Geller D.A., and Forstermann U. Cytokine induction of NO synthase II in human DLD-1 cells: roles of the JAK-STAT, AP-1 and NF-kappaB-signaling pathways. Br. J. Pharmacol. 125 (1998) 193-201
40. de Vera M.E., Shapiro R.A., Nussler A.K., Mudgett J.S., Simmons R.L., Morris Jr. S.M., Billiar T.R., and Geller D.A. Transcriptional regulation of human inducible nitric oxide synthase (NOS2) gene by cytokines: initial analysis of the human NOS2 promoter. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 1054-1059
41. Geller D.A., de Vera M.E., Russell D.A., Shapiro R.A., Nussler A.K., Simmons R.L., and Billiar T.R. A central role for IL-1 beta in the in vitro and in vivo regulation of hepatic inducible nitric oxide synthase. IL-1 beta induces hepatic nitric oxide synthesis. J. Immunol. 155 (1995) 4890-4898
42. Samardzic T., Jankovic V., Stosic-Grujicic S., and Trajkovic V. STAT1 is required for iNOS activation, but not IL-6 production in murine fibroblasts. Cytokine 13 (2001) 179-182
43. Shen S., Yu S., Binek J., Chalimoniuk M., Zhang X., Lo S.C., Hannink M., Wu J., Fritsche K., Donato R., and Sun G.Y. Distinct signaling pathways for induction of type II NOS by IFNgamma and LPS in BV-2 microglial cells. Neurochem. Int. 47 (2005) 298-307
44. Dong Z., Staroselsky A.H., Qi X., Xie K., and Fidler I.J. Inverse correlation between expression of inducible nitric oxide synthase activity and production of metastasis in K-1735 murine melanoma cells. Cancer Res. 54 (1994) 789-793
45. Gerecitano J., Perle M.A., and Vilcek J. Transcriptional basis for the differences in inducible nitric oxide synthase (iNOS) expression between nonmetastatic and metastatic murine melanoma cell lines. J. Interferon Cytokine Res. 19 (1999) 393-405
46. Rocha I.M., and Guillo L.A. Lipopolysaccharide and cytokines induce nitric oxide synthase and produce nitric oxide in cultured normal human melanocytes. Arch. Dermatol. Res. 293 (2001) 245-248
47. Xie Q.W., Whisnant R., and Nathan C. Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon gamma and bacterial lipopolysaccharide. J. Exp. Med. 177 (1993) 1779-1784
48. Yu X., Kennedy R.H., and Liu S.J. JAK2/STAT3, not ERK1/2, mediates interleukin-6-induced activation of inducible nitric-oxide synthase and decrease in contractility of adult ventricular myocytes. J. Biol. Chem. 278 (2003) 16304-16309
49. Lowenstein C.J., Alley E.W., Raval P., Snowman A.M., Snyder S.H., Russell S.W., and Murphy W.J. Macrophage nitric oxide synthase gene: two upstream regions mediate induction by interferon gamma and lipopolysaccharide. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 9730-9734
50. Lopez-Collazo E., Hortelano S., Rojas A., and Bosca L. Triggering of peritoneal macrophages with IFN-alpha/beta attenuates the expression of inducible nitric oxide synthase through a decrease in NF-kappaB activation. J. Immunol. 160 (1998) 2889-2895
51. Da Silva J., Pierrat B., Mary J.L., and Lesslauer W. Blockade of p38 mitogen-activated protein kinase pathway inhibits inducible nitric-oxide synthase expression in mouse astrocytes. J. Biol. Chem. 272 (1997) 28373-28380
52. Giri S., Jatana M., Rattan R., Won J.S., Singh I., and Singh A.K. Galactosylsphingosine (psychosine)-induced expression of cytokine-mediated inducible nitric oxide synthases via AP-1 and C/EBP: implications for Krabbe disease. Faseb J. 16 (2002) 661-672
53. Kristof A.S., Marks-Konczalik J., and Moss J. Mitogen-activated protein kinases mediate activator protein-1-dependent human inducible nitric-oxide synthase promoter activation. J. Biol. Chem. 276 (2001) 8445-8452
54. Pance A., Chantome A., Reveneau S., Bentrari F., and Jeannin J.F. A repressor in the proximal human inducible nitric oxide synthase promoter modulates transcriptional activation. Faseb J. 16 (2002) 631-633
55. Cho I.J., Lee A.K., Lee S.J., Lee M.G., and Kim S.G. Repression by oxidative stress of iNOS and cytokine gene induction in macrophages results from AP-1 and NF-kappaB inhibition mediated by B cell translocation gene-1 activation. Free Radic. Biol. Med. 39 (2005) 1523-1536
56. Marks-Konczalik J., Chu S.C., and Moss J. Cytokine-mediated transcriptional induction of the human inducible nitric oxide synthase gene requires both activator protein 1 and nuclear factor kappaB-binding sites. J. Biol. Chem. 273 (1998) 22201-22208
57. Okada S., Obata S., Hatano M., and Tokuhisa T. Dominant-negative effect of the c-fos family gene products on inducible NO synthase expression in macrophages. Int. Immunol. 15 (2003) 1275-1282
58. Baldwin Jr. A.S. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 14 (1996) 649-683
59. Shaulian E., and Karin M. AP-1 as a regulator of cell life and death. Nat. Cell Biol. 4 (2002.) E131-E136
60. Lazar-Molnar E., Hegyesi H., Pallinger E., Kovacs P., Toth S., Fitzsimons C., Cricco G., Martin G., Bergoc R., Darvas Z., Rivera E.S., and Falus A. Inhibition of human primary melanoma cell proliferation by histamine is enhanced by interleukin-6. Eur. J. Clin. Invest. 32 (2002) 743-749
61. Mouawad R., Soubrane C., Rixe O., Khayat D., and Spano J.P. An unexpected inverse correlation between soluble epidermal growth factor receptor and interleukin-6 in metastatic malignant melanoma patients. Melanoma Res. 16 (2006) 335-340
62. Peters M., Muller A.M., and Rose-John S. Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. Blood 92 (1998) 3495-3504
63. Lavabre-Bertrand T., Exbrayat C., Liautard J., Gaillard J.P., Baskevitch P.P., Poujol N., Duperray C., Bourquard P., and Brochier J. Detection of membrane and soluble interleukin-6 receptor in lymphoid malignancies. Br. J. Haematol. 91 (1995) 871-877
64. Ozbek S., Peters M., Breuhahn K., Mann A., Blessing M., Fischer M., Schirmacher P., Mackiewicz A., and Rose-John S. The designer cytokine hyper-IL-6 mediates growth inhibition and GM-CSF-dependent rejection of B16 melanoma cells. Oncogene 20 (2001) 972-979
65. Lechner M., Lirk P., and Rieder J. Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin. Semin. Cancer Biol. 15 (2005) 277-289
66. Lala P.K., and Chakraborty C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol. 2 (2001) 149-156
67. Ekmekcioglu S., Tang C.H., and Grimm E.A. NO news is not necessarily good news in cancer. Curr. Cancer Drug Targets 5 (2005) 103-115
68. Salvucci O., Carsana M., Bersani I., Tragni G., and Anichini A. Antiapoptotic role of endogenous nitric oxide in human melanoma cells. Cancer Res. 61 (2001) 318-326
69. Tang C.H., and Grimm E.A. Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines. J. Biol. Chem. 279 (2004) 288-298
70. Xie K., and Fidler I.J. Therapy of cancer metastasis by activation of the inducible nitric oxide synthase. Cancer Metastasis Rev. 17 (1998) 55-75
71. Konopka T.E., Barker J.E., Bamford T.L., Guida E., Anderson R.L., and Stewart A.G. Nitric oxide synthase II gene disruption: implications for tumor growth and vascular endothelial growth factor production. Cancer Res. 61 (2001) 3182-3187
72. Qiu H., Orr F.W., Jensen D., Wang H.H., McIntosh A.R., Hasinoff B.B., Nance D.M., Pylypas S., Qi K., Song C., Muschel R.J., and Al-Mehdi A.B. Arrest of B16 melanoma cells in the mouse pulmonary microcirculation induces endothelial nitric oxide synthase-dependent nitric oxide release that is cytotoxic to the tumor cells. Am. J. Pathol. 162 (2003) 403-412